What is Flamel Technologies?
Flamel Technologies SA is a pharmaceutical company focused on blending internally developed high-value products with its advanced drug delivery capabilities. The company's portfolio includes marketed products like Bloxiverz and manufactured components for Coreg CR®, leveraging its proprietary Micropump® and Medusa drug delivery platforms. These platforms aim to create safer and more efficacious drug formulations for unmet medical needs, with several Medusa-based products having successfully completed clinical trials. Headquartered in Lyon, France, Flamel Technologies also maintains operations in St. Louis, Missouri, and manufacturing facilities in Pessac, France.
How much funding has Flamel Technologies raised?
Flamel Technologies has raised a total of $15M across 1 funding round:
Debt
$15M
Debt (2013): $15M, investors not publicly disclosed
What's next for Flamel Technologies?
The recent major strategic investment indicates a phase of scaling and further development for Flamel Technologies. This capital infusion is likely to accelerate the advancement of its proprietary pipeline of niche specialty pharmaceutical products and further refine its innovative drug delivery platforms, including LiquiTime® and Trigger Lock. The company's focus on addressing unmet medical needs positions it for continued growth and potential market expansion within the specialty pharma and biotech sectors.
See full Flamel Technologies company page
